Centre for Eye Research Australia, Royal Victorian Eye & Ear Hospital, University of Melbourne, Melbourne, Victoria, Australia.
Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia.
Acta Ophthalmol. 2024 Aug;102(5):e736-e745. doi: 10.1111/aos.16634. Epub 2024 Jan 16.
PURPOSE: Economic evaluations of interventions for ocular disease require utility scores that accurately represent quality of life in the target population. This study aimed to describe the distribution of EQ-5D-5L utility values among Australian adults with symptomatic inherited retinal diseases (IRDs) and to assess the relationship between these scores and vision-related quality of life. METHODS: A survey was administered predominantly online in 2021. Participants completed the EQ-5D-5L general health utility instrument, the EQ vertical visual analogue scale (EQ-VAS) and the National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25). Self-reported IRD diagnoses were classified as being associated with central or widespread retinal involvement. RESULTS: Responses from 647 participants aged 18-93 years were included, 50.1% were men and 77.6% had an IRD associated with widespread retinal involvement. The majority reported no problems with self-care and no pain/discomfort but did report anxiety/depression and problems with work, study, housework, or family/leisure activities. Most people with widespread involvement reported problems with mobility. Median EQ-5D-5L utility was 0.88 and 0.91 among people with widespread and central involvement, respectively (age and sex-adjusted p = 0.029); and median EQ-VAS was 75 and 80, respectively (adjusted p = 0.003). A moderate curvilinear correlation was observed between EQ-5D-5L and NEI-VFQ-25 composite score (Spearman's ρ 0.69), but not all people with poor vision-related quality of life had low EQ-5D-5L utility values. CONCLUSIONS: EQ-5D-5L health utility values are correlated with vision-related quality of life among adults with IRDs. However, the EQ-5D-5L may not be sensitive to the full impact of vision impairment on quality of life.
目的:干预眼部疾病的经济评估需要能够准确反映目标人群生活质量的效用评分。本研究旨在描述澳大利亚有症状遗传性视网膜疾病(IRD)成人的 EQ-5D-5L 效用值分布,并评估这些评分与视觉相关生活质量之间的关系。
方法:2021 年主要通过在线方式进行了一项调查。参与者完成了 EQ-5D-5L 一般健康效用仪器、EQ 垂直视觉模拟量表(EQ-VAS)和国家眼科研究所视觉功能问卷(NEI-VFQ-25)。自我报告的 IRD 诊断被归类为与中央或广泛视网膜受累相关。
结果:纳入了 647 名年龄在 18-93 岁之间的参与者的回复,其中 50.1%为男性,77.6%的人患有与广泛视网膜受累相关的 IRD。大多数人表示在自理、疼痛/不适方面没有问题,但报告有焦虑/抑郁和在工作、学习、家务或家庭/休闲活动方面存在问题。大多数广泛受累的人报告在移动方面存在问题。在广泛和中央受累人群中,EQ-5D-5L 效用的中位数分别为 0.88 和 0.91(年龄和性别调整后 p=0.029);EQ-VAS 的中位数分别为 75 和 80,分别(调整后 p=0.003)。在 EQ-5D-5L 和 NEI-VFQ-25 综合评分之间观察到中度曲线相关(Spearman's ρ 0.69),但并非所有视觉相关生活质量较差的人都具有较低的 EQ-5D-5L 效用值。
结论:在患有 IRD 的成年人中,EQ-5D-5L 健康效用值与视觉相关生活质量相关。然而,EQ-5D-5L 可能无法敏感地反映视力损害对生活质量的全面影响。
Health Qual Life Outcomes. 2016-9-20
Health Qual Life Outcomes. 2024-1-3
J Glob Health. 2023-2-17
Eur J Health Econ. 2020-11
Health Qual Life Outcomes. 2021-7-20
J Clin Med. 2025-5-6